Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

On the basis of potential additive or synergistic immunostimulatory antitumor effects, in this phase 1 study, the authors evaluated the combination of sunitinib and tremelimumab (CP‐675206; an antibody against cytotoxic T‐lymphocyte–associated antigen 4 [CTLA4]) in patients with metastatic renal cell carcinoma (mRCC) was evaluated.

[1]  John A Thompson.  Metastatic renal cell carcinoma: current standards of care. , 2009, Clinical journal of oncology nursing.

[2]  U. Harmenberg,et al.  Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  B. Rini,et al.  Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients , 2009, Clinical Cancer Research.

[4]  B. Redman,et al.  Phase I/II trial of tremelimumab in patients with metastatic melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  B. Rini,et al.  Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients , 2008, Clinical Cancer Research.

[6]  A. Hauschild,et al.  Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma , 2008 .

[7]  A. Hauschild,et al.  A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma , 2008 .

[8]  B. Rini,et al.  Recent Progress in the Management of Advanced Renal Cell Carcinoma , 2007, CA: a cancer journal for clinicians.

[9]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[10]  B. Comin-Anduix,et al.  Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Carbone,et al.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.

[12]  B. Rini,et al.  Phase I dose escalation trial of tremelimumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Raymond,et al.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Cancer Therapy Evaluation Program.  Common Terminology Criteria for Adverse Events v3.0 (CTCAE) , 2003 .

[15]  D. Carbone,et al.  Errata , 1996, Nature Medicine.